<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article article-type="letter">
  <?properties open_access?>
  <!-- Original-type: sc-->
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id>
      <journal-title>British Journal of Cancer</journal-title>
      <issn pub-type="ppub">0007-0920</issn>
      <issn pub-type="epub">1532-1827</issn>
      <publisher>
        <publisher-name>Nature Publishing Group</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">14974481</article-id>
      <article-id pub-id-type="pmc">2409560</article-id>
      <article-id pub-id-type="pii">6601301</article-id>
      <article-id pub-id-type="doi">10.1038/sj.bjc.6601303</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Short Communication</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Fatal outcome of a hypersensitivity reaction to paclitaxel: a critical review of premedication regimens</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Kloover</surname>
            <given-names>J S</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
          <xref ref-type="corresp" rid="caf1">*</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Bakker</surname>
            <given-names>M A den</given-names>
          </name>
          <xref ref-type="aff" rid="aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Gelderblom</surname>
            <given-names>H</given-names>
          </name>
          <xref ref-type="aff" rid="aff3">3</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Meerbeeck</surname>
            <given-names>J P van</given-names>
          </name>
          <xref ref-type="aff" rid="aff4">4</xref>
          <xref ref-type="author-notes" rid="note1">5</xref>
        </contrib>
      </contrib-group>
      <aff id="aff1"><label>1</label><sup>1</sup>Department of Pulmonology, Erasmus MC, Postbus 2040, 3000 CA Rotterdam, The Netherlands</aff>
      <aff id="aff2"><label>2</label><sup>2</sup>Department of Pathology, Josephine Nefkens Institute, Erasmus MC, Rotterdam, The Netherlands</aff>
      <aff id="aff3"><label>3</label><sup>3</sup>Department of Clinical Oncology, LUMC, Leiden, The Netherlands</aff>
      <aff id="aff4"><label>4</label><sup>4</sup>Department of Respiratory Diseases, University Hospital, Ghent, Belgium</aff>
      <author-notes>
        <corresp id="caf1"><label>*</label>Author for correspondence: <email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mailto:jeroenkloover@tiscali.nl">jeroenkloover@tiscali.nl</email></corresp>
        <fn fn-type="present-address" id="note1">
          <label>5</label>
          <p>On behalf of The Rotterdam Oncologic Thoracic Study group, ROTS.</p>
        </fn>
      </author-notes>
      <pub-date pub-type="epub">
        <day>20</day>
        <month>01</month>
        <year>2004</year>
      </pub-date>
      <pub-date pub-type="ppub">
        <day>26</day>
        <month>01</month>
        <year>2004</year>
      </pub-date>
      <volume>90</volume>
      <issue>2</issue>
      <fpage>304</fpage>
      <lpage>305</lpage>
      <history>
        <date date-type="received">
          <day>28</day>
          <month>02</month>
          <year>2003</year>
        </date>
        <date date-type="accepted">
          <day>23</day>
          <month>07</month>
          <year>2003</year>
        </date>
      </history>
      <copyright-statement>Copyright 2004, Cancer Research UK</copyright-statement>
      <copyright-year>2004</copyright-year>
      <permissions>
        <copyright-holder>Cancer Research UK</copyright-holder>
      </permissions>
      <abstract>
        <p>Hypersensitivity reactions (HSRs) to paclitaxel are frequently encountered in patients receiving this antitumour drug. Administration of histamine H1- and H2-receptor antagonists and corticosteroids has been shown to reduce significantly the risk of developing an HSR in patients receiving taxanes. In this case report, we describe the fatal outcome of an HSR in a patient receiving paclitaxel despite short-course premedication. The level of evidence supporting the short-course i.v. premedication schedule is challenged, as it is not compatible with the pharmacokinetic properties of dexamethasone.</p>
      </abstract>
      <kwd-group>
        <kwd>paclitaxel</kwd>
        <kwd>hypersensitivity reaction</kwd>
        <kwd>anaphylaxis</kwd>
        <kwd>dexamethasone</kwd>
        <kwd>premedication</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <p>A hypersensitivity reaction (HSR), defined as any immunological response to a drug resulting in an adverse reaction, is a frequent side effect during paclitaxel infusion (<xref ref-type="other" rid="bib17">Zanotti and Markman, 2001</xref>). Symptoms vary from mild pruritus to anaphylaxis (<xref ref-type="other" rid="bib16">Weiss <italic>et al</italic>, 1990</xref>). The occurrence of HSRs can be influenced by administration of an appropriate premedication. Oral premedication with dexamethasone at a dose of 20&#x2009;mg given orally at 12 and 6&#x2009;h before infusion of paclitaxel has been shown to reduce the incidence of paclitaxel-induced HSRs significantly (<xref ref-type="other" rid="bib16">Weiss <italic>et al</italic>, 1990</xref>; <xref ref-type="other" rid="bib13">Rowinsky and Donehower, 1995</xref>; <xref ref-type="other" rid="bib4">Kintzel, 2001</xref>). However, due to logistical factors, short-course premedication with intravenously (i.v.) administered dexamethasone given 30&#x2009;min prior to paclitaxel infusion has become customary in many centres. Retrospective analyses comparing the effectivity of both prophylactic regimens have been performed. However, outcomes from these studies are inconsistent. In this report, the rationale of short-course i.v. dexamethasone is discussed at the occasion of a fatal anaphylactic event after paclitaxel infusion with the latter premedication regimen.</p>
    <sec>
      <title>CASE REPORT</title>
      <p>A 52-year-old male with good performance status was referred for treatment of biopsy-proven non-small-cell lung cancer (NSCLC). The primary lesion was located in the left upper lobe with multiple pleural metastases and thoracoscopic invasion of the mediastinum. The patient was offered palliative chemotherapy consisting of paclitaxel (200&#x2009;mg/m<sup>&#x2212;2</sup>) as a 3-hourly infusion followed by carboplatin (area under curve 6) infusion, both as 3-weekly cycles. Premedication consisted of i.v. administered clemastine (2&#x2009;mg), ranitidine (50&#x2009;mg) and dexamethasone (10&#x2009;mg), and was given 30&#x2009;min prior to paclitaxel infusion. Shortly after the start of the paclitaxel infusion, the patient complained of acute progressive pain in his lower back, breathlessness and chest pain. He developed general distress, followed by cardiac arrest. Cardiopulmonary resuscitation, which included intubation and respiratory support, was started without delay and remained unsuccessful. An autopsy was performed confirming the presence of a stage IV NSCLC extending beyond the parietal pleura into the adjacent soft tissue. Additional findings included mild left ventricular hypertrophy and biventricular dilatation with moderate atherosclerosis of the coronary arteries. Other causes of acute death, such as myocardial infarction, could be excluded. The spleen and liver were congested, consistent with fluid accumulation in the third space.</p>
    </sec>
    <sec>
      <title>DISCUSSION</title>
      <p>In this report, we describe the fatal outcome of an acute-onset HSR after paclitaxel infusion, despite administration of a widely accepted regimen of premedication. Postmortem findings after anaphylactic reactions and especially medication-induced anaphylaxis are generally nonspecific and include pulmonary congestion and oedema. Findings indicating an immunological (allergic) cause of death as cutaneous erythema, upper airway oedema and pettecchial haemorrhages are rarely seen (<xref ref-type="other" rid="bib12">Pumphrey and Roberts, 2000</xref>).</p>
      <p>Paclitaxel is widely used as antitumour medication in ovarian, breast, non-small-cell lung and other cancers. Owing to the poor insolubility of paclitaxel, the compound requires dissolution in Cremophor EL, a derivative of castor oil.</p>
      <p>Although the incidence of HSR after paclitaxel infusion is estimated to be &lt;44 and &lt;10% for mild and severe HSRs, respectively, fatal outcome is rare (<xref ref-type="other" rid="bib16">Weiss <italic>et al</italic>, 1990</xref>). It is known that HSRs predominantly occur during the first 10&#x2009;min of infusion and are usually restricted to the first two cycles of chemotherapy.</p>
      <p>The aetiology of paclitaxel-associated HSR is multifactorial and several mechanisms have been postulated: (A) an IgE-mediated mast-cell degranulation induced by paclitaxel (<xref ref-type="other" rid="bib16">Weiss <italic>et al</italic>, 1990</xref>) or Cremophor EL (<xref ref-type="other" rid="bib2">Dye and Watkins, 1980</xref>; <xref ref-type="other" rid="bib15">Weiss and Baker, 1987</xref>); (B) a non-IgE-mediated idiosyncratic mast-cell degranulation by paclitaxel or by Cremophor EL (<xref ref-type="other" rid="bib3">Gelderblom <italic>et al</italic>, 2001</xref>) and (C) complement activation (<xref ref-type="other" rid="bib14">Szebeni <italic>et al</italic>, 2001</xref>). The rapid and overwhelming onset of the HSR as observed in our patient is not compatible with the natural course of an IgE hypersensitivity reaction and points towards one of the two other mechanisms.</p>
      <p>Dexamethasone is a long-acting glucocorticoid with a biologic half-life of approximately 48&#x2009;h and noticeable onset of biologic activity after several hours (<xref ref-type="other" rid="bib10">O'Sullivan <italic>et al</italic>, 1997</xref>). Dexamethasone strongly inhibits inflammation, especially cellular-mediated immunity and the production or action of the local mediators of inflammation, such as the prostaglandins and lymphokines. Furthermore, dexamethasone reduces vascular permeability and maintains normal vascular responsiveness to circulating vasoconstrictor factors. Standard premedication with dexamethasone at a dose of 20&#x2009;mg given orally 12 and 6&#x2009;h prior to paclitaxel infusion has been shown to prevent HSR in most cases (<xref ref-type="other" rid="bib16">Weiss <italic>et al</italic>, 1990</xref>; <xref ref-type="other" rid="bib13">Rowinsky and Donehower, 1995</xref>; <xref ref-type="other" rid="bib4">Kintzel, 2001</xref>). Despite this premedication schedule, grade 3/4 HSR still occur in 1&#x2013;2% of patients (<xref ref-type="other" rid="bib6">Kosmidis <italic>et al</italic>, 2002</xref>).</p>
      <p>However, this treatment regimen requires a good compliance by the patients. To avoid rescheduling chemotherapy schemes due to noncompliance, attention was focused on anecdotal cases in which dexamethasone was administered shortly before paclitaxel infusion. In several retrospective series, 5&#x2013;20&#x2009;mg of dexamethasone administered i.v. 3&#x2009;min before the infusion of paclitaxel showed equal success as the oral premedication of historical cases (<xref ref-type="other" rid="bib11">Parikh <italic>et al</italic>, 1996</xref>; <xref ref-type="other" rid="bib1">Bookman <italic>et al</italic>, 1997</xref>; <xref ref-type="other" rid="bib9">Micha <italic>et al</italic>, 1998</xref>; <xref ref-type="other" rid="bib8">Markman <italic>et al</italic>, 1999</xref>; <xref ref-type="other" rid="bib4">Kintzel, 2001</xref>). These reports are in contrast with a recent report by <xref ref-type="other" rid="bib7">Kwon <italic>et al</italic> (2002)</xref>, who retrospectively showed that a single-dose i.v. corticosteroid prophylactic regimen was associated with a significantly higher rate of HSR than the two-dose oral corticosteroid regimen. Bearing in mind the pharmacological properties of dexamethasone, the short-course i.v. premedication schedule given 30&#x2009;min before paclitaxel infusion is unlikely to result in an adequate level of immunosuppression during the infusion of the drug. This may explain the results of Kwon <italic>et al</italic>. This is confirmed by the observation that the incidence of HSRs is not influenced by the dosage of i.v. administered dexamethasone 30&#x2009;min before chemotherapy infusion (<xref ref-type="other" rid="bib5">Koppler <italic>et al</italic>, 2001</xref>). It is possible that retrospective analysis and comparison of the study cohort with historical controls bias the observed protective effect of short-course i.v. prophylaxis by dexamethasone. A prospective randomised study in which the oral pre-treatment regimen is compared with the short-course i.v. administration of dexamethasone is preferable.</p>
      <p>In conclusion, the fatal outcome of the paclitaxel-associated HSR in the patient illustrates the need for continuous awareness and questions the importance of routine i.v. premedication for paclitaxel administration.</p>
    </sec>
  </body>
  <back>
    <ref-list>
      <ref id="bib1">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bookman</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Kloth</surname>
              <given-names>DD</given-names>
            </name>
            <name>
              <surname>Kover</surname>
              <given-names>PE</given-names>
            </name>
            <name>
              <surname>Smolinski</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Ozols</surname>
              <given-names>RF</given-names>
            </name>
          </person-group>
          <article-title>Short-course intravenous prophylaxis for paclitaxel-related hypersensitivity reactions</article-title>
          <source>Ann Oncol</source>
          <year>1997</year>
          <volume>8</volume>
          <fpage>611</fpage>
          <lpage>614</lpage>
          <!--PubMed citation query: 'Ann Oncol||8|611||bib1|'-->
          <pub-id pub-id-type="pmid">9261533</pub-id>
        </citation>
      </ref>
      <ref id="bib2">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dye</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Watkins</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Suspected anaphylactic reaction to Cremophor EL</article-title>
          <source>BMJ</source>
          <year>1980</year>
          <volume>280</volume>
          <fpage>1353</fpage>
          <!--PubMed citation query: 'BMJ||280|1353||bib2|'-->
        </citation>
      </ref>
      <ref id="bib3">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gelderblom</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Verweij</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Nooter</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Sparreboom</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Cremophor EL: the drawbacks and advantages of vehicle delection for drug formulation</article-title>
          <source>Eur J Cancer</source>
          <year>2001</year>
          <volume>37</volume>
          <fpage>1590</fpage>
          <lpage>1598</lpage>
          <!--PubMed citation query: 'Eur J Cancer||37|1590||bib3|'-->
          <pub-id pub-id-type="pmid">11527683</pub-id>
        </citation>
      </ref>
      <ref id="bib4">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kintzel</surname>
              <given-names>PE</given-names>
            </name>
          </person-group>
          <article-title>Prophylaxis for paclitaxel hypersensitivity reactions</article-title>
          <source>Ann Pharmacother</source>
          <year>2001</year>
          <volume>35</volume>
          <fpage>1114</fpage>
          <lpage>1117</lpage>
          <!--PubMed citation query: 'Ann Pharmacother||35|1114||bib4|'-->
          <pub-id pub-id-type="pmid">11573863</pub-id>
        </citation>
      </ref>
      <ref id="bib5">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Koppler</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Heymanns</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Weide</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>Dose reduction of steroid premedication for paclitaxel: no increase of hypersensitivity reactions</article-title>
          <source>Onkologie</source>
          <year>2001</year>
          <volume>24</volume>
          <fpage>283</fpage>
          <lpage>285</lpage>
          <!--PubMed citation query: 'Onkologie||24|283||bib5|'-->
          <pub-id pub-id-type="pmid">11455223</pub-id>
        </citation>
      </ref>
      <ref id="bib6">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kosmidis</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Mylonakis</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Nicolaides</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Kalophonos</surname>
              <given-names>Ch</given-names>
            </name>
            <name>
              <surname>Samantas</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Boukovinas</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Fountzilas</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Skarlos</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Economopoulos</surname>
              <given-names>Th</given-names>
            </name>
            <name>
              <surname>Tsavdaridis</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Papakostas</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Bacoyiannis</surname>
              <given-names>Ch</given-names>
            </name>
            <name>
              <surname>Dimopoulos</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced non-small-cell lung cancer: a phase III randomized trial</article-title>
          <source>J Clin Oncol</source>
          <year>2002</year>
          <volume>20</volume>
          <fpage>3578</fpage>
          <lpage>3585</lpage>
          <!--PubMed citation query: 'J Clin Oncol||20|3578||bib6|'-->
          <pub-id pub-id-type="pmid">12202657</pub-id>
        </citation>
      </ref>
      <ref id="bib7">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kwon</surname>
              <given-names>JS</given-names>
            </name>
            <name>
              <surname>Elit</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Finn</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Hirte</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Mazurka</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Moens</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Trim</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
          <article-title>A comparison of two prophylactic regimens for hypersensitivity reactions to paclitaxel</article-title>
          <source>Gynecol Oncol</source>
          <year>2002</year>
          <volume>84</volume>
          <fpage>420</fpage>
          <lpage>425</lpage>
          <!--PubMed citation query: 'Gynecol Oncol||84|420||bib7|'-->
          <pub-id pub-id-type="pmid">11855881</pub-id>
        </citation>
      </ref>
      <ref id="bib8">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Markman</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Kennedy</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Webster</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Peterson</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Kulp</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Belinson</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>An effective and more convenient drug regimen for prophylaxis against paclitaxel-associated hypersensitivity reactions</article-title>
          <source>J Cancer Res Clin Oncol</source>
          <year>1999</year>
          <volume>125</volume>
          <fpage>427</fpage>
          <lpage>429</lpage>
          <!--PubMed citation query: 'J Cancer Res Clin Oncol||125|427||bib8|'-->
          <pub-id pub-id-type="pmid">10394964</pub-id>
        </citation>
      </ref>
      <ref id="bib9">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Micha</surname>
              <given-names>JP</given-names>
            </name>
            <name>
              <surname>Rettenmaier</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Dillman</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Fraser</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Birk</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Brown</surname>
              <given-names>JV</given-names>
            </name>
          </person-group>
          <article-title>Single-dose dexamethasone paclitaxel premedication</article-title>
          <source>Gynecol Oncol</source>
          <year>1998</year>
          <volume>69</volume>
          <fpage>122</fpage>
          <lpage>124</lpage>
          <!--PubMed citation query: 'Gynecol Oncol||69|122||bib9|'-->
          <pub-id pub-id-type="pmid">9600818</pub-id>
        </citation>
      </ref>
      <ref id="bib10">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>O'Sullivan</surname>
              <given-names>BT</given-names>
            </name>
            <name>
              <surname>Cutler</surname>
              <given-names>DJ</given-names>
            </name>
            <name>
              <surname>Hunt</surname>
              <given-names>GE</given-names>
            </name>
            <name>
              <surname>Walters</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Johnson</surname>
              <given-names>GF</given-names>
            </name>
            <name>
              <surname>Catherson</surname>
              <given-names>ID</given-names>
            </name>
          </person-group>
          <article-title>Pharmacokinetics of dexamethasone and its relationship to dexamethasone suppression test outcome in depressed patients and healthy control subjects</article-title>
          <source>Biol Psychiatry</source>
          <year>1997</year>
          <volume>41</volume>
          <fpage>574</fpage>
          <lpage>584</lpage>
          <!--PubMed citation query: 'Biol Psychiatry||41|574||bib10|'-->
          <pub-id pub-id-type="pmid">9046990</pub-id>
        </citation>
      </ref>
      <ref id="bib11">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Parikh</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Khanolkar</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Advani</surname>
              <given-names>SH</given-names>
            </name>
            <name>
              <surname>Dhabhar</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Chandra</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Safety profile of single-dose dexamethasone premedication for paclitaxel</article-title>
          <source>J Clin Oncol</source>
          <year>1996</year>
          <volume>14</volume>
          <fpage>2189</fpage>
          <lpage>2190</lpage>
          <!--PubMed citation query: 'J Clin Oncol||14|2189||bib11|'-->
          <pub-id pub-id-type="pmid">8683256</pub-id>
        </citation>
      </ref>
      <ref id="bib12">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pumphrey</surname>
              <given-names>RSH</given-names>
            </name>
            <name>
              <surname>Roberts</surname>
              <given-names>ISO</given-names>
            </name>
          </person-group>
          <article-title>Postmortem findings after fatal anaphylactic reactions</article-title>
          <source>J Clin Pathol</source>
          <year>2000</year>
          <volume>53</volume>
          <fpage>273</fpage>
          <lpage>276</lpage>
          <!--PubMed citation query: 'J Clin Pathol||53|273||bib12|'-->
          <pub-id pub-id-type="pmid">10823122</pub-id>
        </citation>
      </ref>
      <ref id="bib13">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rowinsky</surname>
              <given-names>EK</given-names>
            </name>
            <name>
              <surname>Donehower</surname>
              <given-names>RC</given-names>
            </name>
          </person-group>
          <article-title>Paclitaxel (taxol)</article-title>
          <source>N Engl J Med</source>
          <year>1995</year>
          <volume>332</volume>
          <fpage>1004</fpage>
          <lpage>1014</lpage>
          <!--PubMed citation query: 'N Engl J Med||332|1004||bib13|'-->
          <pub-id pub-id-type="pmid">7885406</pub-id>
        </citation>
      </ref>
      <ref id="bib14">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Szebeni</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Alving</surname>
              <given-names>CR</given-names>
            </name>
            <name>
              <surname>Savay</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Formation of complement-activating particles in aqueous solutions of taxol: possible role in hypersensitivity reactions</article-title>
          <source>Int Immunopharmacol</source>
          <year>2001</year>
          <volume>1</volume>
          <fpage>721</fpage>
          <lpage>735</lpage>
          <!--PubMed citation query: 'Int Immunopharmacol||1|721||bib14|'-->
          <pub-id pub-id-type="pmid">11357884</pub-id>
        </citation>
      </ref>
      <ref id="bib15">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Weiss</surname>
              <given-names>RB</given-names>
            </name>
            <name>
              <surname>Baker</surname>
              <given-names>JR</given-names>
              <suffix>Jr</suffix>
            </name>
          </person-group>
          <article-title>Hypersensitivity reactions from antineoplastic agents</article-title>
          <source>Cancer Metast Rev</source>
          <year>1987</year>
          <volume>6</volume>
          <fpage>413</fpage>
          <lpage>432</lpage>
          <!--PubMed citation query: 'Cancer Metast Rev||6|413||bib15|'-->
        </citation>
      </ref>
      <ref id="bib16">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Weiss</surname>
              <given-names>RB</given-names>
            </name>
            <name>
              <surname>Donehower</surname>
              <given-names>RC</given-names>
            </name>
            <name>
              <surname>Wiernik</surname>
              <given-names>PH</given-names>
            </name>
            <name>
              <surname>Ohnuma</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Gralla</surname>
              <given-names>RJ</given-names>
            </name>
            <name>
              <surname>Trump</surname>
              <given-names>DL</given-names>
            </name>
            <name>
              <surname>Baker</surname>
              <given-names>JR</given-names>
            </name>
            <name>
              <surname>Van Echo</surname>
              <given-names>DA</given-names>
            </name>
            <name>
              <surname>Von Hoff</surname>
              <given-names>DD</given-names>
            </name>
            <name>
              <surname>Leyland-Jones</surname>
              <given-names>B</given-names>
            </name>
          </person-group>
          <article-title>Hypersensitivity reactions from taxol</article-title>
          <source>J Clin Oncol</source>
          <year>1990</year>
          <volume>8</volume>
          <fpage>1263</fpage>
          <lpage>1268</lpage>
          <!--PubMed citation query: 'J Clin Oncol||8|1263||bib16|'-->
          <pub-id pub-id-type="pmid">1972736</pub-id>
        </citation>
      </ref>
      <ref id="bib17">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zanotti</surname>
              <given-names>KM</given-names>
            </name>
            <name>
              <surname>Markman</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Prevention and management of antineoplastic-induced hypersensitivity reactions</article-title>
          <source>Drug Saf</source>
          <year>2001</year>
          <volume>24</volume>
          <fpage>767</fpage>
          <lpage>779</lpage>
          <!--PubMed citation query: 'Drug Saf||24|767||bib17|'-->
          <pub-id pub-id-type="pmid">11676304</pub-id>
        </citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
